Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Albuterol Market Hots Up With Lupin ProAir Approval

Analyst Predicts Albuterol ‘End Of The Road’

Executive Summary

The market for generic albuterol sulfate is becoming increasingly commoditized in the US, with Lupin announcing FDA approval for generic ProAir – the Indian company’s first device-based inhalation product in the US. Nevertheless, it remains a lucrative opportunity for ANDA sponsors.

You may also be interested in...



Lupin CEO Says Additional incentives Needed To Make US Manufacturing Viable

Lupin CEO Vinita Gupta has insisted that additional incentives are necessary to make local manufacturing in the US viable. The recently-launched podcast by the US Association for Accessible Medicines, with CEO Dan Leonard as the host, welcomed Gupta who shared details of Lupin’s strategy and how the company plans to keep a firm foot in affordable medicines. 

US Sees Increasing Diversity In Generic Formulations

Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.

Lupin Gets Head Start On Brovana With US Authorized Generic

Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel